Autoimmune Diseases Affecting Hemostasis: A Narrative Review

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Dec 11

PMID 36499042

Authors

Emmanuel J Favaloro

Leonardo Pasalic

Giuseppe Lippi

Affiliations

Soon will be listed here.

Abstract

Hemostasis reflects a homeostatic mechanism that aims to balance out pro-coagulant and anti-coagulant forces to maintain blood flow within the circulation. Simplistically, a relative excess of procoagulant forces can lead to thrombosis, and a relative excess of anticoagulant forces can lead to bleeding. There are a wide variety of congenital disorders associated with bleeding or thrombosis. In addition, there exist a vast array of autoimmune diseases that can also lead to either bleeding or thrombosis. For example, autoantibodies generated against clotting factors can lead to bleeding, of which acquired hemophilia A is the most common. As another example, autoimmune-mediated antibodies against phospholipids can generate a prothrombotic milieu in a condition known as antiphospholipid (antibody) syndrome (APS). Moreover, there exist various autoimmunity promoting environments that can lead to a variety of antibodies that affect hemostasis. Coronavirus disease 2019 (COVID-19) represents perhaps the contemporary example of such a state, with potential development of a kaleidoscope of such antibodies that primarily drive thrombosis, but may also lead to bleeding on rarer occasions. We provide here a narrative review to discuss the interaction between various autoimmune diseases and hemostasis.

Citing Articles

A rare case of postoperative hemorrhage following laparoscopic cholecystectomy - A case report.

Chen M, Cai R, Salameen H, Wang X, Chen P, Ding X Heliyon. 2025; 11(3):e41560.

PMID: 39991251 PMC: 11847240. DOI: 10.1016/j.heliyon.2024.e41560.

Von Willebrand Factor Antigen, Biomarkers of Inflammation, and Microvascular Flap Thrombosis in Reconstructive Surgery.

Rocans R, Zarins J, Bine E, Mahauri I, Deksnis R, Citovica M J Clin Med. 2024; 13(18).

PMID: 39336896 PMC: 11432012. DOI: 10.3390/jcm13185411.

Risk of death, thrombotic and hemorrhagic events in anticoagulated patients with atrial fibrillation and systemic autoimmune diseases: an analysis from a global federated dataset.

Bucci T, Cardamone C, Triggiani M, Ames P, Lip G Clin Res Cardiol. 2024; 113(6):942-950.

PMID: 38446151 PMC: 11108877. DOI: 10.1007/s00392-024-02426-1.

Acquired Hemophilia A after SARS-CoV-2 Infection: A Case Report and an Updated Systematic Review.

Nemeth M, Muhl D, Csontos C, Nagy A, Alizadeh H, Szakacs Z Biomedicines. 2023; 11(9).

PMID: 37760842 PMC: 10526109. DOI: 10.3390/biomedicines11092400.

The Crossroads of the Coagulation System and the Immune System: Interactions and Connections.

Wilhelm G, Mertowska P, Mertowski S, Przysucha A, Struzyna J, Grywalska E Int J Mol Sci. 2023; 24(16).

PMID: 37628744 PMC: 10454528. DOI: 10.3390/ijms241612563.

References

Serrano M, Espinosa G, Serrano A, Cervera R . COVID-19 and the antiphospholipid syndrome. Autoimmun Rev. 2022; 21(12):103206. PMC: 9527199. DOI: 10.1016/j.autrev.2022.103206. View

Alharbi M, Alanazi N, Yousef A, Alanazi N, Alotaibi B, Aljurf M . COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis. Expert Rev Hematol. 2022; 15(2):157-166. PMC: 8862167. DOI: 10.1080/17474086.2022.2029699. View

Stempel J, Podoltsev N, Zeidan A, Lee A, Shallis R . Concealed by the convenient: acquired von Willebrand syndrome in myeloproliferative neoplasm requires a thorough evaluation. Ann Hematol. 2022; 101(11):2559-2561. DOI: 10.1007/s00277-022-04943-3. View

Janjetovic S, Rolling C, Budde U, Schneppenhem S, Schafhausen P, Peters M . Evaluation of different diagnostic tools for detection of acquired von Willebrand syndrome in patients with polycythemia vera or essential thrombocythemia. Thromb Res. 2022; 218:35-43. DOI: 10.1016/j.thromres.2022.08.002. View

Sridharan M, Fylling K, Ashrani A, Chen D, Marshall A, Hook C . Clinical and laboratory diagnosis of autoimmune factor V inhibitors: A single institutional experience. Thromb Res. 2018; 171:14-21. DOI: 10.1016/j.thromres.2018.09.044. View

Favaloro E . Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia. Int J Lab Hematol. 2021; 43(4):559-570. PMC: 8444734. DOI: 10.1111/ijlh.13629. View

Knobl P . Inherited and acquired thrombotic thrombocytopenic purpura (TTP) in adults. Semin Thromb Hemost. 2014; 40(4):493-502. DOI: 10.1055/s-0034-1376883. View

Lippi G, Favaloro E . Strength of Anticoagulation in Moderate to Severe COVID-19 Illness: In Medio Stat Virtus?. Semin Thromb Hemost. 2022; 49(1):81-84. DOI: 10.1055/s-0042-1756186. View

Killian M, van Mens T . Risk of Thrombosis, Pregnancy Morbidity or Death in Antiphospholipid Syndrome. Front Cardiovasc Med. 2022; 9:852777. PMC: 8921454. DOI: 10.3389/fcvm.2022.852777. View

10.

Chaudhary H, Nasir U, Syed K, Labra M, Reggio C, Aziz A . COVID-19-Associated Thrombotic Thrombocytopenic Purpura: A Case Report and Systematic Review. Hematol Rep. 2022; 14(3):253-260. PMC: 9397065. DOI: 10.3390/hematolrep14030035. View

11.

Mahroum N, Lavine N, Ohayon A, Seida R, Alwani A, Alrais M . COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review. Front Immunol. 2022; 13:872683. PMC: 9294236. DOI: 10.3389/fimmu.2022.872683. View

12.

Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati M, Iacoviello L . Different Anticoagulant Regimens, Mortality, and Bleeding in Hospitalized Patients with COVID-19: A Systematic Review and an Updated Meta-Analysis. Semin Thromb Hemost. 2021; 47(4):372-391. DOI: 10.1055/s-0041-1726034. View

13.

Thachil J . COVID-19 Vaccine-Induced Immune Thrombosis with Thrombocytopenia (VITT) and the Shades of Grey in Thrombus Formation. Semin Thromb Hemost. 2021; 48(1):15-18. DOI: 10.1055/s-0041-1735453. View

14.

Melmed A, Kovoor A, Flippo K . Acquired hemophilia A after vaccination against SARS-CoV-2 with the mRNA-1273 (Moderna) vaccine. Proc (Bayl Univ Med Cent). 2022; 35(5):683-685. PMC: 9373746. DOI: 10.1080/08998280.2022.2071121. View

15.

Federici A, Budde U, Castaman G, Rand J, Tiede A . Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost. 2013; 39(2):191-201. DOI: 10.1055/s-0033-1334867. View

16.

Webert K . Acquired hemophilia A. Semin Thromb Hemost. 2012; 38(7):735-41. DOI: 10.1055/s-0032-1326779. View

17.

Miyakis S, Lockshin M, Atsumi T, Branch D, Brey R, Cervera R . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306. DOI: 10.1111/j.1538-7836.2006.01753.x. View

18.

Cuker A . The Case for Therapeutic-Intensity Anticoagulation in Patients with COVID-19-Associated Moderate Illness. Semin Thromb Hemost. 2022; 49(1):76-78. DOI: 10.1055/s-0042-1756709. View

19.

Vandevelde A, Devreese K . Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances. J Clin Med. 2022; 11(8). PMC: 9025581. DOI: 10.3390/jcm11082164. View

20.

Franchini M, Lippi G, Favaloro E . Acquired inhibitors of coagulation factors: part II. Semin Thromb Hemost. 2012; 38(5):447-53. DOI: 10.1055/s-0032-1305779. View